Nakano M, et al. - Between January 1, 2015 and January 31, 2017, researchers enrolled 3,012 subjects with chronic hepatitis C virus (HCV) infection (with or without cirrhosis) to study HCC recurrence and any relevant predictive factors after curative treatment for HCC. They recorded the development of HCC recurrence in 47.2% of patients over a mean follow-up period of 29.4 months. The 1-, 2-, and 3-year cumulative HCC recurrence rates were 27.1%, 43.4%, and 50.8%, respectively, with a median time to recurrence of 34.0 months. They observed the α-fetoprotein (AFP) level prior to direct-acting antiviral agent (DAA) therapy and the number of curative treatments for HCC before DAA therapy as risk factors for HCC recurrence.